Medtronic’s PFA-led acceleration and MiniMed separation create a credible path from defensive blue chip to 13% annualized five-year returns.
Overview
Medtronic is the largest pure-play medical-technology manufacturer, serving hospitals, clinicians, and ASCs through Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its recurring implant, consumables, equipment, and monitoring revenue is supported by clinical evidence, more than 10,000 field representatives, and high switching costs. **FY26 revenue rose 8.4% reported and 5.8% organically to $36.364 billion**, the strongest top-line performance in ten years; adjusted EPS was $5.53 and free cash flow was $5.426 billion. Cardiovascular led growth at 12.0% reported and 9.3% organically, while PFA delivered 145% global growth in Q4. The MiniMed IPO and planned full distribution within 12–15 months simplify the parent toward B2B hospital technology, although separation costs are projected at $300–$500 million through FY29. **The $87.16 share price compares with $105.07 DCF value and a $143.51 probability-weighted five-year target.** Near-term catalysts include FY27 organic growth guidance of 6.75%–7.25%, PFA share gains, Hugo RAS FDA progress, tariff relief, and completion of the MiniMed separation.